Effects of a Fully Humanized Type II Anti-CD20 Monoclonal Antibody on Peripheral and CNS B Cells in a Transgenic Mouse Model of Multiple Sclerosis
Successful therapy with anti-CD20 monoclonal antibodies (mAbs) has reinforced the key role of B cells in the immunopathology of multiple sclerosis (MS). This study aimed to determine the effects of a novel class of anti-CD20 mAbs on vascular and extravascular central nervous system (CNS)-infiltratin...
Main Authors: | Sabine Tacke, Rittika Chunder, Verena Schropp, Eduard Urich, Stefanie Kuerten |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/23/6/3172 |
Similar Items
-
Anti-CD20 monoclonal antibodies: reviewing a revolution
by: J. M. L. Casan, et al.
Published: (2018-12-01) -
New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
by: Biswanath Basu, et al.
Published: (2022-02-01) -
In Silico Designed Gain-of-Function Variants of Complement C2 Support Cytocidal Activity of Anticancer Monoclonal Antibodies
by: Aleksandra Urban, et al.
Published: (2022-03-01) -
The Acquisition of Complement-Dependent Cytotoxicity by the Type II Anti-CD20 Therapeutic Antibody Obinutuzumab
by: Alicja Kuźniewska, et al.
Published: (2023-12-01) -
A Biphasic COVID-19 Clinical Course in Anti-CD20 Treated Patients: Case Series and Review of the Literature
by: Noa Bigman-Peer, et al.
Published: (2022-08-01)